Belite Bio (BLTE) Net Cash Flow (2024 - 2025)

Belite Bio (BLTE) recorded quarterly Net Cash Flow of $196.0 million in Q4 2025, up 2039.73% quarter-over-quarter from $9.2 million in Q4 2024, and up 2039.73% on a YoY basis from $9.2 million in Q4 2024.

Belite Bio (BLTE) Net Cash Flow (2024 - 2025) Analysis & Trends

Belite Bio's Net Cash Flow history runs 2 years deep, the most recent figure standing at $196.0 million for Q4 2025.

  • In Q4 2025, Net Cash Flow rose 2039.73% year-over-year to $196.0 million; the TTM figure through Mar 2026 stood at $196.0 million (up 2039.73% YoY), while the FY2025 annual figure was $321.1 million, up 671.31% from the prior year.
  • Net Cash Flow was $196.0 million for Q4 2025 at Belite Bio, up from $9.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $196.0 million in Q4 2025 to a low of $9.2 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 2.44 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 625.70 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -2.44 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 457.40 Mn
9 Abivax 91.96 Bn 91.96 Bn - 664,983.53
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn -152.20 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 196.00 Mn
Dec 31, 2025 196.00 Mn
Dec 31, 2024 9.16 Mn
Dec 31, 2024 9.16 Mn